glp-1 receptor agonists and cancer risk in adults with obesity changes body mass and composition in overweight or with or without type 2 diabetes mellitus: a systematic review and meta-analysis GLP1 Receptor Agonists—Effects beyond Obesity
Description
doi: 10.1111/j.1463-1326.2011.01357.x
Postdoctoral Innovative Talent Support Plan of China (BX20220070 to Z.C.)
Nat Rev Cardiol (2019) 16(4):20312
Patients were randomized 1:1 to receive subcutaneous semaglutide 2.4 mg once weekly or placebo as an adjunct to standard-of-care therapy for CVD, such as cholesterol-modifying medications, antiplatelet therapies and antihypertensive agents
Athauda, D
For you as someone considering or using these medications, the practical takeaway is straightforward
